@FierceBiotech: RaNA banks $55M to get its RNA drugs into the clinic. News | Follow @FierceBiotech
@JohnCFierce: Cara Therapeutics scores another positive PhII for lead opioid. More | Follow @JohnCFierce
@DamianFierce: The world is terrible. Article | Follow @DamianFierce
> Watertown, MA-based Forma Therapeutics has tapped Novartis ($NVS) vet John Hohneker as its new head of R&D. Hohneker most recently served as senior VP and global head of development for the immunology and dermatology franchise at Novartis. Release
> Ablynx has extended its pact with Merck ($MRK) to work on an increased number of immune checkpoint modulator targets. Release
> SutroVax, a spinout of Sutro Biopharma, raised $22 million in Series A cash to support its work on vaccines for infectious diseases. Story
> Gilead Sciences ($GILD) is touting positive Phase III results in a study testing whether an in-development, one-pill combination of four HIV treatments can measure up to its blockbuster Viread. The trial met its main goal of noninferiority, and the new pill notched a statistically significant improvement in patients with lower viral loads. More
Medical Device News
@FierceMedDev: Oxford Nanopore reels in $109M to ramp up R&D. FierceDiagnostics story | Follow @FierceMedDev
@StacyALawrence: iHealth expands its retail, connected medical device empire and looks to move into. Report | Follow @StacyALawrence
@VarunSaxena2: UPDATED: St. Jude to buy Thoratec for $3.4B, will pair its heart pump with the cardioMEMs patient monitor. Story | Follow @VarunSaxena2
@EmilyWFierce: Nonprofit snags $5.2M grant to investigate U.S. drug pricing. FiercePharma article | Follow @EmilyWFierce
> Bard hit with FDA warning letter affecting its vena cava filters. Report
> Harvard Wyss Institute spins out apnea prevention startup MediCollector. Article
Pharma News
@FiercePharma: NIAID scientists one step closer to 'universal' flu vaccine. More | Follow @FiercePharma
@CarlyHFierce: Earnings season is better than Christmas. I mean, I actually like most things better than Christmas, but point still stands. | Follow @CarlyHFierce
> Bristol-Myers smashes Q2 as hep C meds rake in overseas sales. Story
> Eli Lilly's Q2 beats the Street as newer products, animal health buy pitch in. Article
Vaccines News
> Pfizer talks up 'comprehensive' vaccines business. Report
> Health officials detail need for $2B vaccines fund. Item
> NIAID scientists one step closer to 'universal' flu vaccine. Article
> SutroVax bags $22M Series A to develop vaccines for infectious diseases. Story
> Sanofi's dengue vaccine anticipated on profitability 'high end.' More
CRO News
> Biocon might spin out its CRO after taking it public. More
> Huntingdon and Harlan raise up to $125M to fund their future together. News
> PRA doubles down on the hunt for new R&D talent. Report
> Covance and LabCorp open a new R&D center to pool their expertise. Story
> AMRI bets $174M on manufacturing with latest buyout. Article
Pharma Manufacturing News
> Sun may only get 3 of Ranbaxy's 4 banned plants ready for U.S. market. Item
> Capsugel expanding plant in Scotland. More
> Lupin gets first U.S. manufacturing base with buyout of GAVIS. Report
> Patheon, DPx unload chemical operations to tighten focus on pharma. Story
> Sandoz gives Novartis a boost, but 3 plants still get the boot. Article
Pharma Asia News
> From the pharma C-suite: Novartis on Asia, emerging markets in Q2. Item
> Lee family victory in Samsung shareholder challenge sets stage for biologics ramp up. Report
> India's drug and CRO manufacturing travails gather pace as New Delhi calls on diplomats to help. Article
> Industry groups lobby against Japan reimbursement price cuts. Story
> China state-owned drug firms move to direct consumer sales, prescriptions next? More